Assenagon Asset Management
PTLA

Assenagon Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Assenagon Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-23,153
Closed -$628K – 1165
2019
Q2 		$628K Buy
+23,153
New +$726K ﹤0.01% 813

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Assenagon Asset Management's PTLA Position: Q3 2019 in Review

Assenagon Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2019, closing a stake of 23,153 shares — an estimated $628K sold.

Assenagon Asset Management first reported a position in PTLA in Q2 2019 and held it in 1 quarter. The position peaked at $628K in Q2 2019. 212 funds tracked by Wall St. Rank hold PTLA as of Q3 2019.

  • Assenagon Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Assenagon Asset Management sold 23,153 Portola Pharmaceuticals, Inc. shares in Q3 2019, an estimated $628K.
  • Assenagon Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Assenagon Asset Management's Portola Pharmaceuticals, Inc. position peaked at $628K in Q2 2019.
  • 212 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2019.

Based on Assenagon Asset Management's 13F filing for Q3 2019, filed 16 Oct 2019.